Learning from a Clinical Cohort for HCV Vaccine Development

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2019 Apr 18

PMID 30992137

Citations 2

Authors

Florian Wrensch

Zhen-Yong Keck

Steven K H Foung

Thomas F Baumert

Affiliations

Soon will be listed here.

Citing Articles

Modeling of randomized hepatitis C vaccine trials: Bridging the gap between controlled human infection models and real-word testing.

Mackesy-Amiti M, Gutfraind A, Tatara E, Collier N, Cotler S, Page K PNAS Nexus. 2025; 4(1):pgae564.

PMID: 39777292 PMC: 11704953. DOI: 10.1093/pnasnexus/pgae564.

Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C.

Nishio A, Hasan S, Park H, Park N, Salas J, Salinas E Nat Commun. 2022; 13(1):5446.

PMID: 36114169 PMC: 9481596. DOI: 10.1038/s41467-022-33035-z.

Hepatitis C virus: A critical approach to who really needs treatment.

Kouroumalis E, Voumvouraki A World J Hepatol. 2022; 14(1):1-44.

PMID: 35126838 PMC: 8790391. DOI: 10.4254/wjh.v14.i1.1.

References

Baumert T, Fauvelle C, Chen D, Lauer G . A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014; 61(1 Suppl):S34-44. DOI: 10.1016/j.jhep.2014.09.009. View

Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E . Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005; 79(10):6023-34. PMC: 1091689. DOI: 10.1128/JVI.79.10.6023-6034.2005. View

Osburn W, Fisher B, Dowd K, Urban G, Liu L, Ray S . Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2009; 138(1):315-24. PMC: 2889495. DOI: 10.1053/j.gastro.2009.09.017. View

Sacks-Davis R, Grebely J, Dore G, Osburn W, Cox A, Rice T . Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis. 2015; 212(9):1407-19. PMC: 4601911. DOI: 10.1093/infdis/jiv220. View

Law M, Maruyama T, Lewis J, Giang E, Tarr A, Stamataki Z . Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2007; 14(1):25-7. DOI: 10.1038/nm1698. View

Carlsen T, Pedersen J, Prentoe J, Giang E, Keck Z, Mikkelsen L . Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology. 2014; 60(5):1551-62. PMC: 4415877. DOI: 10.1002/hep.27298. View

Keck Z, Saha A, Xia J, Wang Y, Lau P, Krey T . Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol. 2011; 85(20):10451-63. PMC: 3187491. DOI: 10.1128/JVI.05259-11. View

Jardine J, Julien J, Menis S, Ota T, Kalyuzhniy O, McGuire A . Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013; 340(6133):711-6. PMC: 3689846. DOI: 10.1126/science.1234150. View

Merat S, Bru C, van de Berg D, Molenkamp R, Tarr A, Koekkoek S . Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. J Hepatol. 2019; 71(1):14-24. DOI: 10.1016/j.jhep.2019.02.013. View

10.

Giang E, Dorner M, Prentoe J, Dreux M, Evans M, Bukh J . Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012; 109(16):6205-10. PMC: 3341081. DOI: 10.1073/pnas.1114927109. View

11.

Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S . Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010; 202(6):862-6. PMC: 2931414. DOI: 10.1086/655902. View

12.

Pestka J, Zeisel M, Blaser E, Schurmann P, Bartosch B, Cosset F . Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007; 104(14):6025-30. PMC: 1851610. DOI: 10.1073/pnas.0607026104. View

13.

Choo Q, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G . Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994; 91(4):1294-8. PMC: 43144. DOI: 10.1073/pnas.91.4.1294. View

14.

Cowton V, Singer J, Gifford R, Patel A . Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Front Immunol. 2018; 9:1470. PMC: 6036255. DOI: 10.3389/fimmu.2018.01470. View

15.

Fuerst T, Pierce B, Keck Z, Foung S . Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. Front Microbiol. 2018; 8:2692. PMC: 5775222. DOI: 10.3389/fmicb.2017.02692. View

16.

de Jong Y, Dorner M, Mommersteeg M, Xiao J, Balazs A, Robbins J . Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014; 6(254):254ra129. PMC: 4312107. DOI: 10.1126/scitranslmed.3009512. View

17.

Gerlach J, Diepolder H, Jung M, Gruener N, Schraut W, Zachoval R . Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999; 117(4):933-41. DOI: 10.1016/s0016-5085(99)70353-7. View

18.

Keck Z, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C . Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology. 2016; 64(6):1922-1933. PMC: 5115987. DOI: 10.1002/hep.28850. View

19.

Velazquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J . Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. J Virol. 2018; 93(4). PMC: 6364003. DOI: 10.1128/JVI.01909-18. View

20.

Keck M, Wrensch F, Pierce B, Baumert T, Foung S . Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. Front Immunol. 2018; 9:1194. PMC: 5991293. DOI: 10.3389/fimmu.2018.01194. View